AI Insight
Researchers screened an antiviral compound library for antibacterial activity against Klebsiella pneumoniae (Kp), a drug-resistant pathogen that colonizes the gut and frequently causes serious infections such as bacteremia and pneumonia. They identified six antiviral compounds with previously undescribed activity against Kp, though efficacy proved strain-specific and dependent on biological context simulating gut conditions. The study proposes repurposing existing antiviral drugs as a novel decolonization strategy targeting Kp in the gastrointestinal tract before systemic dissemination occurs.
Why it matters
Intestinal colonization by Kp often precedes invasive infection, and no established decolonization therapies currently exist, making the identification of repurposed drugs with anti-Kp activity a potentially significant step toward reducing infection risk in vulnerable patients. If validated in further studies, this approach could offer a faster route to clinical application compared to developing entirely new antibacterial agents.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Klebsiella pneumoniae (Kp) is a common antibiotic-resistant pathogen that colonizes the gastrointestinal tract and can disseminate to peripheral sites, causing a range of infections including bacteremia, urinary tract infections, and pneumonia. Intestinal colonization with Kp is a risk factor for subsequent infection, as the colonizing strain frequently corresponds to the infecting isolate. Accordingly, targeting Kp prior to dissemination at the site of colonization through decolonization strategies offers a promising approach to mitigate infection risk. In this study, we evaluated the repurposing of existing drugs with previously uncharacterized antibacterial activity as candidates for Kp decolonization. To this end, we screened an antiviral compound library for their activity against Kp. We identified and validated six compounds with previously uncharacterized activity against Kp. Then, we screened a library of clinical Kp strains against a subset of these compounds and found that their activity was strain-specific to degrees that differed based on the compound. Finally, we tested the activity of these compounds in conditions relevant to the human gut. We determined the activity of these candidates was dependent on biological context. Collectively, these findings support further investigation of antiviral drugs as potential gut decolonization therapies for Kp.
Source: Repurposing antiviral drugs as a new avenue for Klebsiella pneumoniae decolonization